A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients.

Saved in:
Bibliographic Details
Title: A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients.
Authors: García-Torralba E; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Navarro Manzano E; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Luengo-Gil G; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., De la Morena Barrio P; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Chaves Benito A; Department of Pathology, University Hospital Morales Meseguer, Murcia, Spain., Pérez-Ramos M; Department of Pathology, University Hospital Morales Meseguer, Murcia, Spain., Álvarez-Abril B; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Ivars Rubio A; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., García-Garre E; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Ayala de la Peña F; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., García-Martínez E; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.; Medical School, Catholic University of Murcia, Murcia, Spain.
Source: Frontiers in oncology [Front Oncol] 2023 May 29; Vol. 13, pp. 1182725. Date of Electronic Publication: 2023 May 29 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2023.1182725